TransMedics Group Inc., a medical technology company specializing in organ transplant therapies, announced on August 1, 2025, the granting of stock options and restricted stock units as part of its employment inducement strategy. On July 28, 2025, the company awarded non-qualified stock options to purchase 21,458 shares of common stock and 14,283 restricted stock units to 14 new employees. These grants were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) and the TransMedics Inducement Plan. The stock options have an exercise price of $105.24, reflecting the market closing price on the grant date, and have a 10-year term. Vesting begins with 25% of options vesting after the first year and the rest monthly over three years, contingent on continued employment. Restricted stock units will vest in equal parts over four years.